Search

Your search keyword '"Multiple sclerosis -- Conferences, meetings and seminars"' showing total 166 results
Start Over Descriptor "Multiple sclerosis -- Conferences, meetings and seminars"
166 results on '"Multiple sclerosis -- Conferences, meetings and seminars"'

2. bit.bio to Unveil iPSC Advancements and ioCells Toolkit at Society for Neuroscience 2024 Annual Conference

Subjects
Charles River Laboratories Corp. -- Conferences, meetings and seminars, Agricultural industry -- Conferences, meetings and seminars, Multiple sclerosis -- Conferences, meetings and seminars, Conferences and conventions -- Conferences, meetings and seminars, Business, Business, international
Abstract

* bit.bio's ioSensory Neurons pain research was selected for presentation at SfN's Neuroscience 2024 press conference, and it was chosen from over 10,500+ submissions. * bit.bio will host an expert [...]

Published
2024

3. Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024

Subjects
Multiple sclerosis -- Conferences, meetings and seminars, Conferences and conventions -- Conferences, meetings and seminars, Myasthenia gravis -- Conferences, meetings and seminars, General interest, News, opinion and commentary
Abstract

EMERYVILLE: Kyverna Therapeutics has issued the following news release: Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today [...]

Published
2024

4. Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024

Subjects
Multiple sclerosis -- Conferences, meetings and seminars, Myasthenia gravis -- Conferences, meetings and seminars
Abstract

Company symposium to highlight case reports from 11 patients with stiff-person syndrome, myasthenia gravis and multiple sclerosis reinforcing KYV-101's initial efficacy and safety profile and broad potential in B cell-driven [...]

Published
2024

5. TG Therapeutics Announces Presentations for BRIUMVI(R) (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting

Subjects
Multiple sclerosis -- Conferences, meetings and seminars, Banking, finance and accounting industries, Business, Briumvi (Medication)
Abstract

NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI[sup.(R) ](ublituximab-xiiy) in patients with [...]

Published
2024

6. Helius Medical Technologies to Exhibit at 2024 CMSC Annual Meeting, Marking a Year of Achievements: Making PoNS More Available to People with MS

Subjects
Multiple sclerosis -- Conferences, meetings and seminars, Banking, finance and accounting industries, Business
Abstract

NEWTOWN, Pa., May 23, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) ('Helius' or the 'Company'), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for [...]

Published
2024

7. TG Therapeutics Announces Additional Data Presentations for BRIUMVI(R) (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

Subjects
Multiple sclerosis -- Conferences, meetings and seminars, Banking, finance and accounting industries, Business, American Academy of Neurology -- Conferences, meetings and seminars, Briumvi (Medication)
Abstract

NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced two additional data presentations from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI[sup.(R)] [...]

Published
2024

8. TG Therapeutics Announces Presentation of Data for BRIUMVI(R) (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting

Subjects
Multiple sclerosis -- Conferences, meetings and seminars, Banking, finance and accounting industries, Business, American Academy of Neurology -- Conferences, meetings and seminars, Briumvi (Medication)
Abstract

NEW YORK, April 15, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI(R) [...]

Published
2024

9. Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology

Subjects
T cells -- Conferences, meetings and seminars, Multiple sclerosis -- Conferences, meetings and seminars, PET imaging -- Conferences, meetings and seminars, Monoclonal antibodies -- Conferences, meetings and seminars, Banking, finance and accounting industries, Business
Abstract

NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: https://www.globenewswire.com/Tracker?data=0pyXE_MqnBZE8xEjgyW7v3vLYNJJJ6vezwZc_vxcEXTtyf1uKNsgjP2y1uBWbnuDpL3itp9U21fuGWqoFSCnbiZ8UHk4TrZBocCNbr1yZTAhkvwm01MlBKNsd8ETMipz) ('Tiziana' or the 'Company'), a biotechnology company developing breakthrough neuro-immunomodulation therapies, today announced an upcoming oral [...]

Published
2024

10. Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology

Subjects
Multiple sclerosis -- Conferences, meetings and seminars, PET imaging -- Conferences, meetings and seminars, Biotechnology industry -- Conferences, meetings and seminars, Business, international, American Academy of Neurology -- Conferences, meetings and seminars
Abstract

(GLOBE NEWSWIRE via COMTEX) -- NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ('Tiziana' or the 'Company'), a biotechnology company developing breakthrough neuro-immunomodulation therapies, [...]

Published
2024

11. Helius Medical to highlight PoNS Therapy at 2023 CMSC annual meeting

Subjects
Multiple sclerosis -- Conferences, meetings and seminars, Business, News, opinion and commentary
Abstract

Helius Medical Technologies announces its participation in the prestigious Consortium of Multiple Sclerosis Centers, CMSC, Annual Meeting. Helius will spotlight its Portable Neuromodulation Stimulator device, which can improve gait deficit [...]

Published
2023

12. Helius Medical showcasing PoNS device at AAN annual meeting

Subjects
Multiple sclerosis -- Conferences, meetings and seminars, Business, News, opinion and commentary
Abstract

Helius Medical Technologies announced it will exhibit at the American Academy of Neurology Annual Meeting for the first time since its Portable Neuromodulation Stimulator device became commercially available in both [...]

Published
2023

13. Octave Updates on Data on Its MSDA Test at CMSC 2022 Annual Meeting

Subjects
Medical tests -- Conferences, meetings and seminars, Multiple sclerosis -- Conferences, meetings and seminars, Arts and entertainment industries
Abstract

Octave reported data focused on the company's novel MS Disease Activity (MSDA) test. According to a media release, the data was shared in a poster presentation at the recent Consortium [...]

Published
2022

14. Helius Medical presents on PoNS Therapy at CMSC Annual Meeting

Subjects
Multiple sclerosis -- Conferences, meetings and seminars, Exercise therapy -- Conferences, meetings and seminars, Business, News, opinion and commentary
Abstract

Helius Medical Technologies announced that a poster detailing the benefits of the Company's Portable Neuromodulation Stimulator Therapy combined with a therapeutic exercise program was presented at the 2022 Consortium of [...]

Published
2022

15. PROSPECTS CONTINUE TO IMPROVE FOR PEOPLE WITH MS BUT DISEASE MANAGEMENT IN OLDER ADULTS PRESENTS CHALLENGES, REPORTS LANCET SEMINAR

Subjects
Aged -- Conferences, meetings and seminars, Multiple sclerosis -- Conferences, meetings and seminars, Diagnostic imaging -- Conferences, meetings and seminars, News, opinion and commentary, University at Buffalo -- Conferences, meetings and seminars
Abstract

BUFFALO, N.Y. -- The following information was released by the University at Buffalo - SUNY: By Ellen Goldbaum Release Date: November 8, 2023 BUFFALO, N.Y. - The past five years [...]

Published
2023

16. The Neuro's Killam Seminar Series explores inflammation in multiple sclerosis - The Tribune

Subjects
T cells -- Conferences, meetings and seminars, Inflammation -- Conferences, meetings and seminars, Multiple sclerosis -- Conferences, meetings and seminars, Seminars -- Conferences, meetings and seminars, B cells -- Conferences, meetings and seminars, News, opinion and commentary, Sports and fitness
Abstract

The Killam Seminar Series hosted a seminar about inflammation in multiple sclerosis at The Montreal Neurological Institute-Hospital (The Neuro) on Oct. 31. The seminar series invited Roberta Magliozzi, associate professor [...]

Published
2023

17. Anokion to Participate in BofA Healthcare Trailblazers Conference

Subjects
Multiple sclerosis -- Conferences, meetings and seminars, Health care industry -- Conferences, meetings and seminars, Conferences and conventions -- Conferences, meetings and seminars, Health care industry, Business, Business, international
Abstract

CAMBRIDGE, Mass. & LAUSANNE, Switzerland -- Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, announced today that Deborah Geraghty, Ph.D., president and [...]

Published
2023

18. Immunic to Participate in Scientific Conferences in October

Subjects
Immunic Inc. -- Conferences, meetings and seminars, Multiple sclerosis -- Conferences, meetings and seminars, Pharmaceutical industry -- Conferences, meetings and seminars, General interest, News, opinion and commentary
Abstract

NEW YORK: Immunic, Inc. has issued the following news release: Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory [...]

Published
2023

19. Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference

Subjects
Nervous system diseases -- Conferences, meetings and seminars, Multiple sclerosis -- Conferences, meetings and seminars, Neurosciences -- Conferences, meetings and seminars, Banking, finance and accounting industries, Business
Abstract

-- Attendees may request 1 x 1 meeting with management at https://www.globenewswire.com/Tracker?data=7UN6xyyHY0F7KhrkXVxNxPJjC0M1mUmp1R5xOAwT9Q4TB8G0Ja3JVt_tEzeUVVxvkKOvzmFsrKCr_fBiKWg1eKNHQroKYsPcPn8Cwlk4KGA= -- PALO ALTO, Calif. and MIAMI, Fla., Sept. 07, 2023 (GLOBE NEWSWIRE) -- https://www.globenewswire.com/Tracker?data=iJ73PSlT89g7jFgJLpSuuTDype_pKzp2VidReA8kxz6Ni0Iw68CVpZI31swCIrAtaVHsnZrP5XCYipKvJ12Z8GlkTw5QPkjbii8LfOEgC1w= (NASDAQ: KTTA) ('Pasithea' or [...]

Published
2023

20. Helius Medical announces poster to be presented at CMSC annual conference

Subjects
Multiple sclerosis -- Conferences, meetings and seminars, Conferences and conventions -- Conferences, meetings and seminars, Business, News, opinion and commentary
Abstract

Helius Medical Technologies announced that an abstract highlighting real-world data, which shows the impact of translingual neurostimulation as a rehabilitation therapy to improve gait in people with multiple sclerosis, MS, [...]

Published
2022

21. Octave Presented New Data at CMSC Annual Meeting 2023, Adding to Growing Evidence Supporting All Dimensions of its Comprehensive Precision Care Solution for Multiple Sclerosis

Subjects
Multiple sclerosis -- Conferences, meetings and seminars, General interest, News, opinion and commentary
Abstract

MENLO PARK: Octave, a leading neuroscience precision care company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, today announced the presentation of new data [...]

Published
2023

22. TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI(r) (ublituximab-xiiy) in Multiple Sclerosis at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting

Subjects
Multiple sclerosis -- Conferences, meetings and seminars, General interest, News, opinion and commentary, Briumvi (Medication) -- Product development
Abstract

NEW YORK: TG Therapeutics, Inc. has issued the following press release: TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 [...]

Published
2023

23. TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI(R) (ublituximab-xiiy) in Multiple Sclerosis at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting

Subjects
Multiple sclerosis -- Conferences, meetings and seminars, Banking, finance and accounting industries, Business, Briumvi (Medication) -- Product development
Abstract

NEW YORK, June 02, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI(R) [...]

Published
2023

24. Octave Presents New Data at CMSC Annual Meeting 2023, Adding to Growing Evidence Supporting All Dimensions of its Comprehensive Precision Care Solution for Multiple Sclerosis

Subjects
Patient compliance -- Conferences, meetings and seminars, Multiple sclerosis -- Conferences, meetings and seminars, Business, Business, international
Abstract

MENLO PARK, Calif. -- Octave, a leading neuroscience precision care company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, today announced the presentation of [...]

Published
2023

25. TG Therapeutics Announces Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI(r) (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting

Subjects
Multiple sclerosis -- Conferences, meetings and seminars, General interest, News, opinion and commentary, Briumvi (Medication) -- Product development
Abstract

NEW YORK: TG Therapeutics, Inc. has issued the following news release: TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the details of an upcoming oral presentation, highlighting data from the ULTIMATE [...]

Published
2023

26. Helius to Highlight Innovative PoNS Therapy(TM) at the 2023 Consortium of Multiple Sclerosis Centers Annual Meeting, in Commemoration of World MS Day

Subjects
Multiple sclerosis -- Conferences, meetings and seminars, Anniversaries -- Conferences, meetings and seminars, Banking, finance and accounting industries, Business
Abstract

NEWTOWN, Pa., May 24, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies (Nasdaq:HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for gait deficits, is excited to announce [...]

Published
2023

27. ALS & MS Clinical Data from Clene's CNM-Au8(r) Featured in Multiple Presentations at the 2023 American Academy of Neurology Annual Meeting

Subjects
Multiple sclerosis -- Conferences, meetings and seminars, Clinical trials -- Conferences, meetings and seminars, General interest, News, opinion and commentary
Abstract

SALT LAKE CITY: Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, Clene) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of [...]

Published
2023

28. TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI(r) (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 75th Annual Meeting

Subjects
Multiple sclerosis -- Conferences, meetings and seminars, Conferences and conventions -- Conferences, meetings and seminars, General interest, News, opinion and commentary, American Academy of Neurology -- Conferences, meetings and seminars, Briumvi (Medication) -- Product development
Abstract

NEW YORK: TG Therapeutics, Inc. has issued the following news release: TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting data from the ULTIMATE I & II Phase 3 trials [...]

Published
2023

29. TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI(R) (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 75th Annual Meeting

Subjects
Multiple sclerosis -- Conferences, meetings and seminars, Conferences and conventions -- Conferences, meetings and seminars, Banking, finance and accounting industries, Business, American Academy of Neurology -- Conferences, meetings and seminars, Briumvi (Medication) -- Product development
Abstract

NEW YORK, April 25, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting data from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI[sup.(R)] (ublituximab-xiiy) [...]

Published
2023

30. Helius Medical Technologies to Spotlight Expanded Authorizations for its PoNS Device at 2023 American Academy of Neurology Annual Meeting, Booth 1685

Subjects
Multiple sclerosis -- Conferences, meetings and seminars, General interest, News, opinion and commentary
Abstract

NEWTOWN: Helius Medical Technologies, Inc. has issued the following press release: Helius Medical Technologies (NASDAQ: HSDT) today announced it will exhibit at the American Academy of Neurology (AAN) Annual Meeting [...]

Published
2023

31. TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the American Academy of Neurology 75th Annual Meeting

Subjects
Multiple sclerosis -- Conferences, meetings and seminars, Monoclonal antibodies -- Conferences, meetings and seminars, General interest, News, opinion and commentary, American Academy of Neurology -- Conferences, meetings and seminars, Briumvi (Medication) -- Product development
Abstract

NEW YORK: TG Therapeutics, Inc. has issued the following news release: TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data from the ULTIMATE I & [...]

Published
2023

32. Octave Presents New Data at CMSC Annual Meeting 2023

Subjects
Medical research -- Conferences, meetings and seminars, Medicine, Experimental -- Conferences, meetings and seminars, Nervous system diseases -- Conferences, meetings and seminars, Multiple sclerosis -- Conferences, meetings and seminars, Business, Business, international, Telecommunications industry
Abstract

Octave, a neuroscience precision care company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, reported the presentation of new data on its MS-specific MRI [...]

Published
2023

33. Octave Presents New Data at CMSC Annual Meeting 2023, Adding to Growing Evidence Supporting All Dimensions of its Comprehensive Precision Care Solution for Multiple Sclerosis

Subjects
Conferences, meetings and seminars, Patient compliance -- Conferences, meetings and seminars, Medical research -- Conferences, meetings and seminars, Multiple sclerosis -- Conferences, meetings and seminars, Medicine, Experimental -- Conferences, meetings and seminars
Abstract

2023 JUN 23 (NewsRx) -- By a News Reporter-Staff News Editor at Health & Medicine Week -- Octave, a leading neuroscience precision care company that delivers a new standard for [...]

Published
2023

34. Helius to Showcase Innovative PoNS Device at ACRM's 2022 Conference - Demonstrating the Power of Neuromodulation to Help People with MS Improve their Gait

Subjects
Multiple sclerosis -- Conferences, meetings and seminars, General interest, News, opinion and commentary
Abstract

NEWTOWN, Pa: Helius Medical Technologies, Inc. has issued the following news release: Helius Medical Technologies (NASDAQ: HSDT) will showcase its innovative new Portable Neuromodulation Stimulator (PoNS(r)) at the 99th annual [...]

Published
2022

35. Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the 'Preserving the Brain' Scientific Conference and Exhibit at the Fondazione Prada in Milan

Subjects
Prada S.p.A. -- Conferences, meetings and seminars, Clothing industry -- Conferences, meetings and seminars, Drugs -- Vehicles, Multiple sclerosis -- Conferences, meetings and seminars, Biotechnology industry -- Conferences, meetings and seminars, Conferences and conventions -- Conferences, meetings and seminars, Chairpersons -- Conferences, meetings and seminars, Drug delivery systems -- Conferences, meetings and seminars, Banking, finance and accounting industries, Business
Abstract

'Effect of nasal anti-CD3 (foralumab) in animal model of Progressive Multiple Sclerosis (MS)' poster exhibit 'Effect of nasal anti-CD3 (foralumab) in healthy subjects' poster exhibit 'Effect of nasal anti-CD3 (foralumab) [...]

Published
2022

36. Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the 'Preserving the Brain' Scientific Conference and Exhibit at the Fondazione Prada in Milan

Subjects
Prada S.p.A. -- Conferences, meetings and seminars, Clothing industry -- Conferences, meetings and seminars, Multiple sclerosis -- Conferences, meetings and seminars, Biotechnology industry -- Conferences, meetings and seminars, Chairpersons -- Conferences, meetings and seminars, Conferences and conventions -- Conferences, meetings and seminars, Business, international
Abstract

(GLOBE NEWSWIRE via COMTEX) -- - 'Effect of nasal anti-CD3 (foralumab) in animal model of Progressive Multiple Sclerosis (MS)' poster exhibit - 'Effect of nasal anti-CD3 (foralumab) in healthy subjects' [...]

Published
2022

37. Octave Presented Data at the CMSC 2022 Annual Meeting Showing its Multiple Sclerosis Disease Activity Biomarker Test Produces Clinical Practice Population Insights

Subjects
Medical tests -- Conferences, meetings and seminars, Multiple sclerosis -- Conferences, meetings and seminars, Business, international
Abstract

MENLO PARK, Calif.: Octave, the developer of a fully-integrated precision care solution built to deliver comprehensive insights that bring scientific clarity to multiple sclerosis (MS), announced data focused on the [...]

Published
2022

38. TG Therapeutics Announces Presentation of Exploratory Analyses from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting

Subjects
Multiple sclerosis -- Conferences, meetings and seminars, Banking, finance and accounting industries, Business
Abstract

NEW YORK, June 03, Jun 03, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NASDAQ:TGTX), EQNX::TICKER_END TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data presentations, including one oral and two poster [...]

Published
2022

40. Helius Medical Announces Poster to Be Presented at the Consortium for Multiple Sclerosis Centers (CMSC) Annual Conference

Subjects
Multiple sclerosis -- Conferences, meetings and seminars, Banking, finance and accounting industries, Business
Abstract

NEWTOWN, May 31, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NASDAQ:HSDT), EQNX::TICKER_END Helius Medical Technologies, Inc. (Nasdaq: HSDT) ('Helius' or the 'Company'), a neurotech company focused on neurological wellness, today [...]

Published
2022

41. FibroBiologics Presents Preclinical Data at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting

Subjects
T cells -- Conferences, meetings and seminars, Multiple sclerosis -- Conferences, meetings and seminars, Business, News, opinion and commentary
Abstract

HOUSTON, May 31, 2022 /PRNewswire/ -- FibroBiologics, a clinical-stage biotechnology company developing fibroblast-based therapeutic cures for chronic diseases, will present preclinical and safety-centered limited clinical trial data for the single-dose [...]

Published
2022

42. TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the 2022 Consortium of Multiple Sclerosis Centers Annual Meeting

Subjects
Multiple sclerosis -- Conferences, meetings and seminars, Banking, finance and accounting industries, Business
Abstract

NEW YORK, May 26, May 26, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NASDAQ:TGTX), EQNX::TICKER_END TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations, including one oral [...]

Published
2022

43. Frequency Therapeutics to Participate in 2022 H.C. Wainwright Global Investment Conference

Subjects
Multiple sclerosis -- Conferences, meetings and seminars, Conferences and conventions -- Conferences, meetings and seminars, General interest, News, opinion and commentary
Abstract

LEXINGTON: FREQUENCY THERAPEUTICS, INC. has issued the following news release: Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a person's innate regenerative [...]

Published
2022

44. INmune Bio, Inc. Presents Data Demonstrating XPro(TM) Promotes Remyelination in Gray Matter at 3rd European Conference on Neuroinflammation

Subjects
Multiple sclerosis -- Conferences, meetings and seminars, Banking, finance and accounting industries, Business
Abstract

Boca Raton, Florida, May 10, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NASDAQ:INMB), EQNX::TICKER_END XPro(TM) Promotes Remyelination in a Cuprizone Model of Multiple Sclerosis(MS) by Improving Macrophage Phagocytosis (clearing) of [...]

Published
2022

45. TG Therapeutics Announces Oral Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the American Academy of Neurology Annual Meeting

Subjects
Multiple sclerosis -- Conferences, meetings and seminars, General interest, News, opinion and commentary
Abstract

NEW YORK: TG Therapeutics, Inc. has issued the following news release: TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that data from the ULTIMATE I & II Phase 3 trials evaluating [...]

Published
2022

46. TG Therapeutics Announces Oral Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the American Academy of Neurology Annual Meeting

Subjects
Multiple sclerosis -- Conferences, meetings and seminars, Banking, finance and accounting industries, Business
Abstract

NEW YORK, April 06, Apr 06, 2022 (GLOBE NEWSWIRE via COMTEX) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that data from the ULTIMATE I & II Phase 3 trials [...]

Published
2022

47. TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the American Academy of Neurology Annual Meeting

Subjects
Multiple sclerosis -- Conferences, meetings and seminars, Banking, finance and accounting industries, Business
Abstract

NEW YORK, April 04, Apr 04, 2022 (GLOBE NEWSWIRE via COMTEX) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data from the ULTIMATE I & II Phase 3 trials evaluating [...]

Published
2022

48. TG Therapeutics announces data presentations at the American Academy of Neurology annual meeting

Subjects
Multiple sclerosis -- Conferences, meetings and seminars, General interest, News, opinion and commentary, American Academy of Neurology -- Conferences, meetings and seminars
Abstract

NEW YORK: TG Therapeutics, Inc., announced the schedule of data presentations, including one oral and three poster presentations, highlighting data from the ULTIMATE I & II Phase 3 trials evaluating [...]

Published
2022

49. TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the American Academy of Neurology Annual Meeting

Subjects
Multiple sclerosis -- Conferences, meetings and seminars, Banking, finance and accounting industries, Business
Abstract

NEW YORK, March 04, Mar 04, 2022 (GLOBE NEWSWIRE via COMTEX) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations, including one oral and three poster [...]

Published
2022

50. Octave Releases Data at the CMSC 2022 Annual Meeting

Subjects
Multiple sclerosis -- Conferences, meetings and seminars, Business, Business, international, Telecommunications industry
Abstract

Octave reported data focused on the company's novel MS Disease Activity (MSDA) test. According to a media release, the data was shared in a poster presentation at the Consortium of [...]

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results